Patent intelligence · US
US 8142809
Compositions and methods to lower glycohemoglobin levels
Compositions and methods to lower glycohemoglobin levels
Patent details — US 8142809
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 27, 2012
- Expiration
- Mar 22, 2032
- Applicant
- Regent of the Univ. of Minnesota
- Claims
- 4
- CPC classes
- A61P, A61P3/10
Quick answer
US 8142809 (Compositions and methods to lower glycohemoglobin levels) is held by Regent of the Univ. of Minnesota. Status: granted. Granted Mar 27, 2012. Expires Mar 22, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Regent of the Univ. of Minnesota
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61P, A61P3/10
More from Regent of the Univ. of Minnesota
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 8142809?
US 8142809 (Compositions and methods to lower glycohemoglobin levels) is held by Regent of the Univ. of Minnesota. Status: granted. Granted Mar 27, 2012. Expires Mar 22, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8142809?
Regent of the Univ. of Minnesota is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 8142809 expire?
Our index shows an expiration date of Mar 22, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.